Navigation Links
Hyperion Therapeutics Secures $40 Million In Series B Round
Date:9/5/2007

SOUTH SAN FRANCISCO, Calif., Sept. 5 /PRNewswire/ -- Hyperion Therapeutics, a biopharmaceutical company focused on the development and commercialization of gastrointestinal and hepatology therapies for the treatment of Urea Cycle Disorders (UCD) and Hepatic Encephalopathy (HE), today announced a $40 million Series B financing. Leading the round was Sofinnova Ventures, with equal commitments by Highland Capital Partners and NEA, all of Menlo Park, CA. WRF Capital of Seattle, WA also participated.

(Logo: http://www.newscom.com/cgi-bin/prnh/20070905/AQW076LOGO )

"We are pleased with the investors' confidence in Hyperion and our team," said Chris Rivera, President and CEO of Hyperion. "The funding will allow us to complete the licensing deal with Medicis Pharmaceutical Corporation (see press release dated August 28, 2007), build out our management team, advance our clinical trials in UCD and HE, and begin the U.S. promotion of the only two FDA-approved compounds for the treatment of UCD, AMMONUL(R) (sodium phenylacetate and sodium benzoate) Injection 10%/10% and BUPHENYL(R) (sodium phenylbutyrate). We look forward to making an immediate impact on patients through efforts to increase the diagnosis, awareness and treatment of UCD with these life-saving drugs."

"The unmet medical need for patients with Urea Cycle Disorders and Hepatic Encephalopathy remain significant," said James Healy, MD, Ph.D, and General Partner of Sofinnova Ventures. "Hyperion is committed to improving the treatment options for these patients."

In response to the announcement of Hyperion's collaboration with Medicis Pharmaceutical Corporation, Cynthia Le Mons, Executive Director of the National Urea Cycle Disorders Foundation commented, "We are excited about the attention and focus the Hyperion team will bring to increasing UCD diagnosis and improving patients' treatment options. We look
'/>"/>

SOURCE Hyperion Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Canadian firm buys Proventiv Therapeutics, makes ex-Bone Care exec CEO
2. TrafficCast secures $2M from Phenomenelle Angels, NEW Capital Fund
3. Perscitus Biosciences secures $250K Commerce loan
4. ProCertus BioPharm secures $2.3M in financing
5. Mirus Bio secures $900K grant to develop research tool
6. BioSystem Development secures angel funding
7. TrafficCast secures $1 million line of credit
8. Medical College secures $9.7M research grant
9. Wausau start up secures $560K for GPS maps
10. Platypus Technologies secures $450K SBIR grant
11. nPoint Secures Second Round of Funding
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2013)... , May 20, 2013 ... (USDA) Agricultural Research Service (ARS) in treatment of ... , Trials to begin in the ... drug delivery technology company Phosphagenics Limited (ASX: ... of Agriculture,s (USDA) Agricultural Research Service (ARS) to develop ...
(Date:5/20/2013)... 20, 2013  MiMedx Group, Inc. (NASDAQ: ... patent protected regenerative biomaterials and bioimplants processed from human ... revolving line of credit with Bank of America.  The ... the Company,s accounts receivable and inventory, allows MiMedx to ...  The facility will be used for general corporate purposes. ...
(Date:5/20/2013)... , May 20, 2013  Dr. ... of nucleic acid research, recently launched a new blog ... with Zon ( zon.trilinkbiotech.com ), focuses on what,s trending ... interviews with industry thought leaders, discussions of research presented ... more. Dr. Zon (PhD Princeton University ...
(Date:5/20/2013)... BALTIMORE , May 20, 2013 ... regional private-public partnership focusing on commercializing market-relevant biohealth ... Central Maryland , today announced ... the first Entrepreneur-in-Residence (EIR) for BHI at the ... Lung and Blood Institute (NHLBI). Dr. Aiyar ...
Breaking Biology Technology:Phosphagenics Signs Research Agreement with the Agricultural Research Service 2Dr. Gerald 'Jerry' Zon Launches New Blog for TriLink BioTechnologies 2BioHealth Innovation, Inc. Names Ram Aiyar as Entrepreneur-in-Residence to NIH National Heart, Lung and Blood Institute 2BioHealth Innovation, Inc. Names Ram Aiyar as Entrepreneur-in-Residence to NIH National Heart, Lung and Blood Institute 3BioHealth Innovation, Inc. Names Ram Aiyar as Entrepreneur-in-Residence to NIH National Heart, Lung and Blood Institute 4
... an Antipsychotic Agent with Less Potential for ... Gain and Metabolic Risks, SAN DIEGO, July 29 ... that the United States Patent and,Trademark Office (USPTO) issued ... provide broad coverage for a pharmaceutical,composition of zonisamide in ...
... (Amex: IMA ), a global leader in rapid ... quarter,ended June 30, 2008., In the second quarter ... compared to net revenue of $155.0 million in the ... to increased,product and service revenue in our Professional Diagnostics ...
... S6973 allows up to 50% sucrose reduction while maintaining the sweet ... ... DIEGO, CA, July 29, 2008 Senomyx, Inc.,(Nasdaq: SNMX ), ... novel flavor ingredients for the food, beverage,and ingredient supply industries, announced ...
Cached Biology Technology:OREXIGEN(R) Therapeutics Receives Notice of Allowance for U.S. Patent Covering the Composition of Matter in OREX-003 2OREXIGEN(R) Therapeutics Receives Notice of Allowance for U.S. Patent Covering the Composition of Matter in OREX-003 3OREXIGEN(R) Therapeutics Receives Notice of Allowance for U.S. Patent Covering the Composition of Matter in OREX-003 4Inverness Medical Innovations Announces Second Quarter 2008 Results 2Inverness Medical Innovations Announces Second Quarter 2008 Results 3Inverness Medical Innovations Announces Second Quarter 2008 Results 4Inverness Medical Innovations Announces Second Quarter 2008 Results 5Inverness Medical Innovations Announces Second Quarter 2008 Results 6Inverness Medical Innovations Announces Second Quarter 2008 Results 7Inverness Medical Innovations Announces Second Quarter 2008 Results 8Inverness Medical Innovations Announces Second Quarter 2008 Results 9Inverness Medical Innovations Announces Second Quarter 2008 Results 10Inverness Medical Innovations Announces Second Quarter 2008 Results 11Inverness Medical Innovations Announces Second Quarter 2008 Results 12Inverness Medical Innovations Announces Second Quarter 2008 Results 13Inverness Medical Innovations Announces Second Quarter 2008 Results 14Inverness Medical Innovations Announces Second Quarter 2008 Results 15Inverness Medical Innovations Announces Second Quarter 2008 Results 16SENOMYX ANNOUNCES INITIATION OF DEVELOPMENT ACTIVITIES FOR NEW SUCROSE ENHANCER 2SENOMYX ANNOUNCES INITIATION OF DEVELOPMENT ACTIVITIES FOR NEW SUCROSE ENHANCER 3SENOMYX ANNOUNCES INITIATION OF DEVELOPMENT ACTIVITIES FOR NEW SUCROSE ENHANCER 4
(Date:5/21/2013)... alter the way genes function without changing the ... the blood of pregnant women during any trimester, ... in the weeks after giving birth, and an ... The findings of the small study involving 52 ... Molecular Psychiatry . , "Postpartum depression can ...
(Date:5/20/2013)... the lungs of the planet, inhales carbon dioxide as it ... grow parts that eventually fall to the ground to decompose ... , Until recently people believed much of the rain forest,s ... in the ocean. University of Washington research showed a decade ... though left open the question of how that was possible, ...
(Date:5/20/2013)... Bristol and published online today in the Journal ... brain and inner ear developed in dinosaurs. , ... with Tom Hbner from the Niederschsische Landesmuseum in Hannover, ... dinosaurs. , The two palaeontologists studied different fossils of ... young (juvenile) individual of approximately three years of ...
Breaking Biology News(10 mins):Genetic predictors of postpartum depression uncovered by Hopkins researchers 2Genetic predictors of postpartum depression uncovered by Hopkins researchers 3Amazon River exhales virtually all carbon taken up by rain forest 2Amazon River exhales virtually all carbon taken up by rain forest 3Fossil brain teaser 2
... Dengue illness, the most common mosquito-borne viral disease in ... and is resurgent in countries such as Argentina, Chile ... economic burden of dengue (pronounced DENgee) in the Western ... researchers published today in the American Journal of ...
... satisfied with everyday life and are involved in leisure ... from the University of Gothenburg, Sweden. Occupational therapist ... how everyday life affects alcohol consumption as part of ... study which has been ongoing at the Sahlgrenska Academy ...
... , Using mathematical concepts, Princeton researchers have developed a ... diseases by calculating which physical properties of biological molecules ... already has identified several potential new drugs that were ... by researchers at Johns Hopkins University. "The power ...
Cached Biology News:Brandeis study shows economic impact of dengue virus in Americas 2Brandeis study shows economic impact of dengue virus in Americas 3Brandeis study shows economic impact of dengue virus in Americas 4Women involved in leisure activities drink less alcohol 2Math may help calculate way to find new drugs for HIV and other diseases 2Math may help calculate way to find new drugs for HIV and other diseases 3
... MagCellect Ferrofluid products perform optimally ... R&D Systems MagCellect Magnet. To ... neodymium iron boron permanent magnet ... 75 mm test tubes or ...
... 0 (or Cap 0-like) RNA into Cap ... been shown to increase in vivo translation ... is seen in Cap 0 structures created ... well as those Cap 0 structures created ...
Request Info...
Form: Ready to use Applications: Western Blot, ELISA...
Biology Products: